These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30049373)

  • 21. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
    Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
    Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
    [No Abstract]   [Full Text] [Related]  

  • 22. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
    Baglivo S; Ricciuti B; Ludovini V; Metro G; Siggillino A; De Giglio A; Chiari R
    J Thorac Oncol; 2018 Aug; 13(8):e145-e147. PubMed ID: 30049377
    [No Abstract]   [Full Text] [Related]  

  • 23. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L; Xia C; Zhang Y; Yang N
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract]   [Full Text] [Related]  

  • 24. A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
    Liang P; Qi L; Guo T; You X; Cui C
    Lung Cancer; 2021 Feb; 152():193-195. PubMed ID: 33388164
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
    Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.
    Jiang W; Sha M; Chen C
    Am J Ther; 2023 Nov-Dec 01; 30(6):e570-e572. PubMed ID: 35482932
    [No Abstract]   [Full Text] [Related]  

  • 28. Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR.
    Zhang X; Jiang W; Yang N; Zhang Y
    Lung Cancer; 2020 Oct; 148():170-172. PubMed ID: 32660759
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.
    Hsia TC; Liang JA; Li CC; Chien CR
    Thorac Cancer; 2018 Nov; 9(11):1398-1405. PubMed ID: 30152040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
    Fang W; Huang Y; Gan J; Shao YW; Zhang L
    J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
    [No Abstract]   [Full Text] [Related]  

  • 31. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
    Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
    Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.
    Wei Q; Zhang J; Chen D; Li S; Liu Y
    Lung Cancer; 2020 Oct; 148():175-176. PubMed ID: 32883519
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Application of radiomics captured from CT to predict the EGFR mutation status and TKIs therapeutic sensitivity of advanced lung adenocarcinoma].
    Yang CS; Chen WD; Gong GZ; Li ZJ; Qiu QT; Yin Y
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):282-287. PubMed ID: 31014053
    [No Abstract]   [Full Text] [Related]  

  • 36. Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach.
    Grosse A; Grosse C
    Cytopathology; 2020 May; 31(3):232-235. PubMed ID: 32072673
    [No Abstract]   [Full Text] [Related]  

  • 37. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H; Wang Y; Su F; Li J; Gong P
    Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A lung adenocarcinoma with rare epidermal growth factor receptor exon 20 V774M mutation was sensitive to osimertinib: A case report and molecular structural analysis.
    Zhuang W; Zhong J; Wang J
    Lung Cancer; 2023 Apr; 178():131-133. PubMed ID: 36842378
    [No Abstract]   [Full Text] [Related]  

  • 39. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
    J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract]   [Full Text] [Related]  

  • 40. Current two EGFR mutations in lung adenocarcinoma -  case report.
    Svaton M; Pesek M; Chudacek Z; Vosmiková H
    Klin Onkol; 2015; 28(2):134-7. PubMed ID: 25882025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.